JHS Svendgaard Laboratories Ltd (JHS) — shareholding pattern, promoter holding, financials and share price
About JHS Svendgaard Laboratories Ltd (JHS)
JHS Svendgaard Laboratories Ltd operates in the Personal Care industry, within the Fast Moving Consumer Goods sector. It trades on the NSE as JHS and on the BSE under scrip code 532771. Its ISIN is INE544H01014.
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of oral and dental products for national and international brands [1]
JHS Svendgaard Laboratories Limited is a leading manufacturer of a comprehensive range of oral care products, including toothbrushes, toothpaste, and mouthwash.
The company operates advanced manufacturing facilities in Himachal Pradesh and caters to various esteemed brands, including Amway, Dabur, and Hindustan Unilever.
Listed peers in Personal Care: Thrive Future Habitats Limited, Ravelcare Ltd, Mohini Health & Hygiene Ltd, Novateor Research Laboratories Ltd, Paramount Cosmetics (India) Ltd.
Valuation & Returns
10 Jul 2026At ₹7.7 a share on 10 Jul 2026, JHS Svendgaard Laboratories Ltd (JHS) was valued at a price-to-book of 0.39x on a book value of ₹19.76 per share as of Mar 2025. Solomo computes return on equity of -1.11% and return on capital employed of -0.8% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 46.1x
- P/B
- 0.39x
- EPS (TTM)
- ₹-0.22
- Book value / share
- ₹19.76
- ROE
- -1.11%
- ROCE
- -0.8%
- ROA
- -0.95%
- Debt / equity
- 0.04x
- Dividend yield
- 0%
- EBITDA margin
- 5.97%
- 52-week range
- ₹6.15 – ₹13.83
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, JHS Svendgaard Laboratories Ltd (JHS) reported revenue of ₹102 crore, net profit of ₹-2 crore and earnings per share of ₹-0.22. That compares with revenue of ₹92 crore and net profit of ₹-20 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹32.7 crore and net profit ₹-3.57 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 86 | 85 | 71 | 92 | 102 |
| Net profit (₹ cr) | -4 | -18 | -4 | -20 | -2 |
| EPS (₹) | -0.62 | 0.62 | -0.52 | -2.31 | -0.22 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -0.93% | -7.10% | 4.81% | 29.94% |
| Profit growth | - | - | - | -386.21% |
| Stock price CAGR | -15% | -22% | -30% | -43% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 33.85% of JHS Svendgaard Laboratories Ltd (JHS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 3.14%. Market capitalisation was ₹67 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: VIJAY MOHAN GOVILA 2.74%, HUF 2.26%, COEUS GLOBAL OPPORTUNITIES FUND 2.06%, M.B. FINMART PRIVATE LIMITED 2.06%, Milky Investment And Trading Company 2.06%, Puran Associates Private Limited 2.06%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 33.85% | - | 3.14% | - | 66.15% |
| Mar 2026 | 33.85% | - | 3.6% | - | 66.15% |
| Dec 2025 | 34.56% | - | 1.57% | - | 65.44% |
| Sep 2025 | 34.56% | - | 1.57% | - | 65.44% |
| Jun 2025 | 34.56% | - | 1.59% | - | 65.44% |
| Mar 2025 | 34.56% | - | 1.6% | - | 65.44% |
| Dec 2024 | 34.56% | - | 1.59% | - | 65.44% |
| Sep 2024 | 34.56% | - | 1.69% | - | 65.44% |